Lupin's Sugammadex Sodium ANDA214338 Receives Approval Status
Lupin's ANDA214338 for Sugammadex Sodium has received an approval status of AP from the FDA.
Published: August 1, 2026
Updated: August 1, 2026
Author: Humanexa Intelligence
Therapeutic area: Anesthesia / Neuromuscular Blockade
Company: Lupin
Asset: Sugammadex
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Lupin
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval status of Lupin's Sugammadex Sodium could significantly impact the competitive landscape in the anesthesia market. This development necessitates a reassessment of market share and pricing strategies for existing Sugammadex products.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for the final approval and market launch timelines for ANDA214338.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.